are a major component of ciliary microtubules and the principal protein subunit of microtubules in the cell cytoplasm.
They show how CaMKII kinase domains can collectively bind and phosphorylate 6-bit bytes, resulting in hexagonally-based patterns of phosphorylated tubulins
in microtubules (Figure).
Both basic and clinical sciences are investigating the family of proteins called the tubulins
, which form microtubules that are proving important in both disease mechanisms and therapies.
are the proteins that form microtubules, which are key components of the cellular cytoskeleton (structural network).
and the microtubules they form are obviously essential components of all eukaryotic cells.
The assembly by [alpha]/[beta] tubulin
dimers is a process requiring nucleotide GTP (guanosine triphosphate) to bind to both [alpha] and [beta] tubulins
Gant Luxton and Kevin Tyler (Northwestern University [NWU], Chicago, IL) demonstrated a rapid association of host tubulins
with the plasma membrane at the site of Trypanosoma cruzi contact.
If they have truly identified the origin of eukaryotic tubulins
, then it would be extremely important," says Jeffery Errington of Oxford University in England, who studies a bacterial protein with actinlike properties (SN: 3/31/01, p.
Rockville, MD) announced that it has entered into an exclusive worldwide license agreement with Celgene Corporation (Summit, NJ) for the development and commercialization of Celgene's small molecule tubulin
inhibitor compounds for the treatment of cancer.
These data demonstrate that indibulin has distinct biologic and molecular properties from other tubulin
binding agents and strongly suggest a very different toxicity profile, particularly with regard to peripheral neuropathy.
Results of the studies presented at the Prague meeting demonstrate that ENMD-1420 (previously CC-5079) inhibits tubulin
polymerization and TNF-Alpha production and has both in vitro and in vivo antitumor activity.
March 24 /PRNewswire-FirstCall/ -- Celgene Corporation announced that it has signed a licensing agreement with EntreMed Corporation (ENMD) whereby EntreMed has been granted rights to the development and commercialization of Celgene's tubulin
inhibitor compounds, a class of orally available, anti-proliferative compounds that have demonstrated, in preclinical models, activity against drug-resistant cancer cells, inhibition of inflammatory cytokines and anti-angiogenic activity.